Herantis Pharma Plc
Company release, 10 February 2025 at 8:35 EET

Herantis Pharma Plc: 2,622,721 new shares registered with the trade register

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Herantis Pharma Plc ("Herantis" or the "Company"), a company developing disease-modifying therapies for Parkinson's disease, announced on 6 February 2025 the result of the offering of new shares in a directed share issue to institutional and other qualified investors (the "Directed Issue"). In the Directed Issue, the Company issued a total of 3,934,084 new shares, of which 2,622,721 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").

Following the registration of the New Shares, the total number of registered shares in the Company is 22,783,454. The New Shares will be issued in the book-entry system (ISIN code FI4000087861) and will be registered on the investors' book-entry accounts after which the New Shares will confer shareholder rights in the Company. The New Shares are expected to be ready for delivery to the investors through Euroclear Finland Ltd on or about 11 February 2025.

Trading in the New Shares is expected to commence on Nasdaq First North Growth Market Finland on or about 11 February 2025.

The remaining 1,311,363 new shares are expected to be registered, delivered to investors and listed later in February 2025.

Herantis Pharma Plc
The Board of Directors

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Ltd

Tel.: +358 9 25 380 225

E-mail: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial, completed in late 2023, demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com